Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report

Gwen van der Wijk, Jacqueline K. Harris, Stefanie Hassel, Andrew D. Davis, Mojdeh Zamyadi, Stephen R. Arnott, Roumen Milev, Raymond W. Lam, Benicio N. Frey, Geoffrey B. Hall, Daniel J. Müller, Susan Rotzinger, Sidney H. Kennedy, Stephen C. Strother, Glenda M. MacQueen, Andrea B. Protzner
doi: https://doi.org/10.1101/2021.01.27.21250490
Gwen van der Wijk
1University of Calgary, Department of Psychology, Calgary, Canada
MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gwen.vanderwijk@ucalgary.ca
Jacqueline K. Harris
2University of Alberta, Department of Computing Science, Edmonton, Canada
3Alberta Machine Intelligence Institute, Edmonton, Canada
Msc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefanie Hassel
4University of Calgary, Cumming School of Medicine, Department of Psychiatry, Calgary, Canada
5Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew D. Davis
6Rotman Research Institute, Baycrest Health Sciences, Toronto, Canada
8Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mojdeh Zamyadi
6Rotman Research Institute, Baycrest Health Sciences, Toronto, Canada
Msc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen R. Arnott
6Rotman Research Institute, Baycrest Health Sciences, Toronto, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roumen Milev
9Queen’s University, Departments of Psychiatry and Psychology, and Providence Care Hospital, Kingston, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond W. Lam
10University of British Columbia, Department of Psychiatry, Vancouver, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benicio N. Frey
11Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada
12Mood Disorders Program and Women’s Health Concerns Clinic, St. Joseph’s Healthcare, Hamilton, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey B. Hall
13Department of Psychology, Neuroscience & Behaviour, McMaster University, and St. Joseph’s Healthcare Hamilton, Hamilton, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Müller
14Department of Psychiatry, University of Toronto, Toronto, Canada
15Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
16Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada
17Institute of Medical Sciences, University of Toronto, Toronto, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Rotzinger
18Centre for Mental Health, University Health Network, Toronto, Canada
19Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sidney H. Kennedy
14Department of Psychiatry, University of Toronto, Toronto, Canada
17Institute of Medical Sciences, University of Toronto, Toronto, Canada
18Centre for Mental Health, University Health Network, Toronto, Canada
20Centre for Depression and Suicide Studies, Unity Health Toronto, Toronto, Canada
21Krembil Research Institute, Toronto Western Hospital, Toronto, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen C. Strother
6Rotman Research Institute, Baycrest Health Sciences, Toronto, Canada
7University of Toronto, Department of Medical Biophysics, Toronto, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenda M. MacQueen
4University of Calgary, Cumming School of Medicine, Department of Psychiatry, Calgary, Canada
5Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea B. Protzner
1University of Calgary, Department of Psychology, Calgary, Canada
5Mathison Centre for Mental Health Research and Education, University of Calgary, Calgary, Canada
22Hotchkiss Brain Institute, Calgary, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Understanding the neural underpinnings of major depressive disorder (MDD) and its treatment could improve treatment outcomes. While numerous studies have been conducted, findings are variable and large sample replications scarce. We aimed to replicate and extend altered functional connectivity findings in the default mode, salience and cognitive control networks (DMN, SN, and CCN respectively) associated with MDD and pharmacotherapy outcomes in a large, multi-site sample. Resting-state fMRI data were collected from 129 patients and 99 controls through the Canadian Biomarker Integration Network in Depression (CAN-BIND) initiative. Symptoms were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS). Connectivity was measured as correlations between four seeds (anterior and posterior DMN, SN and CCN) and all other brain voxels across participants. Partial least squares, a multivariate statistical technique, was used to compare connectivity prior to treatment between patients and controls, and between patients reaching remission early (MADRS ≤ 10 within 8 weeks), late (MADRS ≤ 10 within 16 weeks) or not at all. We replicated previous findings of altered connectivity in the DMN, SN and CCN in patients. In addition, baseline connectivity of the anterior/posterior DMN and SN seeds differentiated patients with different treatment outcomes. Weaker connectivity within the anterior DMN and between the anterior DMN and the SN and CCN characterised early remission; stronger connectivity within the SN and weaker connectivity between the SN and the DMN and CCN was related to late remission, of which the weaker SN – anterior DMN connectivity might specifically be associated with remission to dual pharmacotherapy; and connectivity strength between the posterior DMN and cingulate areas distinguished all three groups, with early remitters showing the strongest connections and non-remitters the weakest. The stability of these baseline patient differences was established in the largest single-site subsample of the data. Our replication and extension of altered connectivity within and between the DMN, SN and CCN highlighted previously reported and new differences between patients with MDD and controls, and revealed features that might predict remission prior to pharmacotherapy.

Trial registration ClinicalTrials.gov: NCT01655706.

Competing Interest Statement

RM has received consulting and speaking honoraria from AbbVie, Allergan, Janssen, KYE, Lundbeck, Otsuka, and Sunovion, and research grants from CAN-BIND, CIHR, Janssen, Lallemand, Lundbeck, Nubiyota, OBI and OMHF. RWL has received honoraria or research funds from Allergan, Manuscript File 2Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, CIHR, CANMAT, Canadian Psychiatric Association, Hansoh, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, MITACS, Ontario Brain Institute, Otsuka, Pfizer, St. Jude Medical, University Health Network Foundation, and VGH-UBCH Foundation. BNF received a research grant from Pfizer, outside of this work. SR has received grant funding from the Ontario Brain Institute and Canadian Institutes of Health Research and holds a patent Teneurin C-Terminal Associated Peptides (TCAP) and methods and uses thereof. Inventors: David Lovejoy, R.B. Chewpoy, Dalia Barsyte, Susan Rotzinger. SHK has received research funding or honoraria from the following sources: Abbott, Alkermes, Allergan, BMS, Brain Canada, Canadian Institutes for Health Research (CIHR), Janssen, Lundbeck, Lundbeck Institute, Ontario Brain Institute, Ontario Research Fund (ORF), Otsuka, Pfizer, Servier, Sunovion and Xian-Janssen. SCS reports partial support from Canadian Biomarker Integration Network in Depression and CIHR (MOP 137097) grants during the conduct of the study, and grants from Ontario Brain Institute, Canadian Foundation for Innovation and Brain Canada, outside the submitted work. He is also the chief scientific officer of the neuroimaging data analysis company ADMdx, Inc (www. admdx.com), which specializes in brain image analysis to enable diagnosis, prognosis and drug effect detection for Alzheimer disease and various other forms of dementia. GW, JKH, SH, ADD, MZ, GBH, DJM, GMM and ABP have no potential conflicts of interest to disclose.

Clinical Trial

NCT01655706

Funding Statement

CAN-BIND is an Integrated Discovery Program carried out in partnership with, and financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, and Servier. Funding and/or in-kind support is also provided by the investigators' universities and academic institutions. All study medications are independently purchased at wholesale market values. We acknowledge support to GW in the form of a Mamdani Family Foundation Graduate Scholarship and Alberta Graduate Excellence Scholarship (AGES: International).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research described in this article has been ethics approved at each participating clinical centre. The ethics committees include: University of British Columbia Clinical Research Ethics Board (Vancouver); University of Calgary Conjoint Health Research Ethics Board (Calgary); University Health Network Research Ethics Board (Toronto); Centre for Addiction and Mental Health Research Ethics Board (Toronto); Hamilton Integrated Research Ethics Board (Hamilton); Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (Kingston). Participants provided written, informed consent for all study procedures.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data analyzed in this paper are not publicly available, but may be made available if permission is granted by the CAN-BIND Investigator's Team and Ontario Brain Institute upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted January 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report
Gwen van der Wijk, Jacqueline K. Harris, Stefanie Hassel, Andrew D. Davis, Mojdeh Zamyadi, Stephen R. Arnott, Roumen Milev, Raymond W. Lam, Benicio N. Frey, Geoffrey B. Hall, Daniel J. Müller, Susan Rotzinger, Sidney H. Kennedy, Stephen C. Strother, Glenda M. MacQueen, Andrea B. Protzner
medRxiv 2021.01.27.21250490; doi: https://doi.org/10.1101/2021.01.27.21250490
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report
Gwen van der Wijk, Jacqueline K. Harris, Stefanie Hassel, Andrew D. Davis, Mojdeh Zamyadi, Stephen R. Arnott, Roumen Milev, Raymond W. Lam, Benicio N. Frey, Geoffrey B. Hall, Daniel J. Müller, Susan Rotzinger, Sidney H. Kennedy, Stephen C. Strother, Glenda M. MacQueen, Andrea B. Protzner
medRxiv 2021.01.27.21250490; doi: https://doi.org/10.1101/2021.01.27.21250490

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Psychiatry and Clinical Psychology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (577)
  • Anesthesia (139)
  • Cardiovascular Medicine (1942)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (331)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
  • Epidemiology (11089)
  • Forensic Medicine (8)
  • Gastroenterology (620)
  • Genetic and Genomic Medicine (3159)
  • Geriatric Medicine (307)
  • Health Economics (561)
  • Health Informatics (2040)
  • Health Policy (862)
  • Health Systems and Quality Improvement (782)
  • Hematology (309)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12702)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2979)
  • Nursing (163)
  • Nutrition (462)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1548)
  • Ophthalmology (475)
  • Orthopedics (185)
  • Otolaryngology (265)
  • Pain Medicine (201)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (910)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (354)
  • Psychiatry and Clinical Psychology (2777)
  • Public and Global Health (5584)
  • Radiology and Imaging (1090)
  • Rehabilitation Medicine and Physical Therapy (631)
  • Respiratory Medicine (757)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (287)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (131)